Pacific Edge's revenue climbs, US future still uncertain

Pacific Edge's revenue climbs, US future still uncertain
Very strong revenue growth, but profit still some distance away (Image: Pacific Edge)
Ella Somers
A boom in Pacific Edge’s Cxbladder test sales boosted the firm’s operating revenue soar by 71%, with a helping hand from favourable exchange rates.Chief executive Peter Meintjes said the 2023 financial year had been a year of “enormous change and achievement” for the cancer diagnostic company.“Pacific Edge is geared for growth,” he told the NZX.Operating revenue for the twelve months to March 31 rose $19.6 million, up from $11.4m in the previous year while total revenue jumped 88% to $26.1m.The revenue climb...

More Markets

Hallenstein stars as NZ stocks drift lower
Markets Market Close

Hallenstein stars as NZ stocks drift lower

The S&P/NZX 50 Index was 42.06 points or 0.32% lower at 13,111.73.

Jamie Gray 26 Sep 2025
Trump to slap new tariffs on pharma
Markets

Trump to slap new tariffs on pharma

Levies on drugs will be imposed on companies that aren’t building plants in the US.

2 Cheap Cars signals branding gear change to chase Turners
Markets

2 Cheap Cars signals branding gear change to chase Turners

At the AGM, a shareholder cited Turners' “very aggressive marketing strategy”.

Gregor Thompson 26 Sep 2025
Hallenstein Glasson reports sales hike to start year
Retail

Hallenstein Glasson reports sales hike to start year

Hallenstein Glasson has reported an early-year sales lift linked to continued growth in its Australian Glassons segment.The clothing retailer reported its full-year earnings for the year to Aug 1 on Friday. Net profit after tax lifted 12.1% to $58.4 million and was at the top end...

Gregor Thompson 26 Sep 2025